IBX Secures Central Ethics Approval - Key Phase 2 Milestone
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The approval from Advarra IRB allows the company to proceed with site activation and patient recruitment, streamlining the trial process across multiple sites. This milestone follows the previously announced FDA Investigational New Drug clearance, solidifying the necessary approvals to commence the trial in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
- MagSense Nanoparticle Manufacturing Update
- IBX Phase 2 Clinical Trial Update
- Appendix 4C and Quarterly Activities Report - June 2026
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
Later from Imagion Biosystems
All Imagion Biosystems news releasesFollow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems